NCT01676818View on ClinicalTrials.gov

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 9, 2012

Primary Completion Date

February 21, 2021

Study Completion Date

August 9, 2021

Conditions
Recurrent Cervical CancerStage IIIA Cervical CancerStage IIIB Cervical CancerStage IVA Cervical CancerStage IVB Cervical Cancer
Interventions
DRUG

eribulin mesylate

Given IV

Trial Locations (1)

90033

USC Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT01676818 - Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer | Biotech Hunter | Biotech Hunter